Delaware
|
|
001-37797
|
|
27-3948465
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock $0.0001 Par Value
|
INNT
|
The Nasdaq Stock Market LLC
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
Item 3.02.
|
Unregistered Sales of Equity Securities.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
Exhibit 4.1
|
|
|
|
|
Innovate Biopharmaceuticals, Inc.
|
|
|
|
|
Date: February 12, 2020
|
By:
|
/s/ Edward J. Sitar
|
|
|
Edward J. Sitar
|
|
|
Chief Financial Officer
|
|
|
|
|
|
|